Memory Cytotoxic T Lymphocyte Responses in Human Immunodeficiency Virus Type 1 (HIV-1)-Negative Volunteers Immunized with a Recombinant Canarypox Expressing gp160 of HIV-1 and Boosted with a Recombinant gp160

A vaccine against human immunodeficiency virus (HIV) should induce virus-specific cytotoxic T lymphocyte (CTL) activity. Immunization of uninfected volunteers with a canarypox virus expressing HIV envelope was carried out in a phase I trial. Two injections of canarypox expressing HIVl MN gp160 (mont...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 1996-10, Vol.174 (4), p.734-738
Main Authors: Fleury, Béatrice, Janvier, Geneviève, Pialoux, Gilles, Buseyne, Florence, Robertson, Michael N., Tartaglia, James, Paoletti, Enzo, Kieny, Marie Paule, Excler, Jean Louis, Rivière, Yves
Format: Article
Language:English
Subjects:
Biological and medical sciences
human immunodeficiency virus 1
Immunodeficiencies
Immunodeficiencies. Immunoglobulinopathies
Immunopathology
Medical sciences
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A vaccine against human immunodeficiency virus (HIV) should induce virus-specific cytotoxic T lymphocyte (CTL) activity. Immunization of uninfected volunteers with a canarypox virus expressing HIV envelope was carried out in a phase I trial. Two injections of canarypox expressing HIVl MN gp160 (months 0 and 1) were followed by two boosts of recombinant envelope protein (months 3 and 6). HIV envelope-specific CTL were detected in peripheral blood mononuclear cells stimulated with autologous HIV-l-infected blast cells. T cell lines were obtained from 18 of 20 donors: CTL were detected at least once following immunization in 7 (39%)of these 18. This activity was mediated by major histocompatibility complex class I-restricted CD3+CD8+ T cells. For two subjects, this activity was still present 2 years after the initial immunization. The CTL responses with this prime-boost regimen are the best observed with any HIV vaccine tested in humans.
ISSN:0022-1899
1537-6613
DOI:10.1093/infdis/174.4.734